These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
281 related items for PubMed ID: 8897164
1. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. Jorgensen JH, Swenson JM, Tenover FC, Barry A, Ferraro MJ, Murray PR, Reller LB. J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164 [Abstract] [Full Text] [Related]
7. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Visalli MA, Jacobs MR, Appelbaum PC. Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703 [Abstract] [Full Text] [Related]
8. Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. Waites K, Johnson C, Gray B, Edwards K, Crain M, Benjamin W. J Clin Microbiol; 2000 May; 38(5):1731-4. PubMed ID: 10790089 [Abstract] [Full Text] [Related]
9. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. Mazzariol A, Koncan R, Vitali LA, Cornaglia G. J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779 [Abstract] [Full Text] [Related]
10. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities. Poulsen RL, Knudsen JD, Petersen MB, Fuursted K, Espersen F, Frimodt-Møller N. APMIS; 1996 Mar; 104(3):227-33. PubMed ID: 8611198 [Abstract] [Full Text] [Related]
11. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Fasola EL, Bajaksouzian S, Appelbaum PC, Jacobs MR. Antimicrob Agents Chemother; 1997 Jan; 41(1):129-34. PubMed ID: 8980768 [Abstract] [Full Text] [Related]
12. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. Davies TA, Kelly LM, Jacobs MR, Appelbaum PC. J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123 [Abstract] [Full Text] [Related]
13. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. Matic V, Kosowska K, Bozdogan B, Kelly LM, Smith K, Ednie LM, Lin G, Credito KL, Clark CL, McGhee P, Pankuch GA, Jacobs MR, Appelbaum PC. Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828 [Abstract] [Full Text] [Related]
14. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group. Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA. Diagn Microbiol Infect Dis; 1999 Jun; 34(2):91-8. PubMed ID: 10354857 [Abstract] [Full Text] [Related]
15. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Pankuch GA, Jacobs MR, Appelbaum PC. Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583 [Abstract] [Full Text] [Related]
16. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group. Barry AL, Thornsberry C, Gavan TL. Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865 [Abstract] [Full Text] [Related]
17. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes. Mason EO, Wald ER, Bradley JS, Barson WJ, Kaplan SL, United States Pediatric Multicenter Pneumococcal Surveillance Study Group. Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838 [Abstract] [Full Text] [Related]
18. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Davies TA, Ednie LM, Hoellman DM, Pankuch GA, Jacobs MR, Appelbaum PC. Antimicrob Agents Chemother; 2000 Jul; 44(7):1894-9. PubMed ID: 10858350 [Abstract] [Full Text] [Related]
19. Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group. Fuchs P, Barry A, Brown S. Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):197-201. PubMed ID: 9665303 [Abstract] [Full Text] [Related]
20. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia. Gosbell IB, Fernandes LA, Fernandes CJ. Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725 [Abstract] [Full Text] [Related] Page: [Next] [New Search]